- Home
- WFF vs LPCN Comparison
WFF vs LPCN Comparison
Compare WFF & LPCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WFF
- LPCN
- Stock Information
- Founded
- WFF 1984
- LPCN 1997
- Country
- WFF Malaysia
- LPCN United States
- Employees
- WFF N/A
- LPCN N/A
- Industry
- WFF Miscellaneous manufacturing industries
- LPCN Biotechnology: Pharmaceutical Preparations
- Sector
- WFF Consumer Discretionary
- LPCN Health Care
- Exchange
- WFF Nasdaq
- LPCN Nasdaq
- Market Cap
- WFF 22.4M
- LPCN 18.2M
- IPO Year
- WFF 2025
- LPCN N/A
- Fundamental
- Price
- WFF $0.97
- LPCN $3.19
- Analyst Decision
- WFF
- LPCN Strong Buy
- Analyst Count
- WFF 0
- LPCN 1
- Target Price
- WFF N/A
- LPCN $8.00
- AVG Volume (30 Days)
- WFF 925.8K
- LPCN 45.3K
- Earning Date
- WFF 11-24-2025
- LPCN 11-06-2025
- Dividend Yield
- WFF N/A
- LPCN N/A
- EPS Growth
- WFF N/A
- LPCN N/A
- EPS
- WFF 0.00
- LPCN N/A
- Revenue
- WFF $4,572,290.00
- LPCN $4,208,119.00
- Revenue This Year
- WFF N/A
- LPCN N/A
- Revenue Next Year
- WFF N/A
- LPCN N/A
- P/E Ratio
- WFF $197.63
- LPCN N/A
- Revenue Growth
- WFF N/A
- LPCN N/A
- 52 Week Low
- WFF $0.81
- LPCN $2.65
- 52 Week High
- WFF $29.26
- LPCN $6.17
- Technical
- Relative Strength Index (RSI)
- WFF N/A
- LPCN 63.61
- Support Level
- WFF N/A
- LPCN $2.65
- Resistance Level
- WFF N/A
- LPCN $3.52
- Average True Range (ATR)
- WFF 0.00
- LPCN 0.16
- MACD
- WFF 0.00
- LPCN 0.06
- Stochastic Oscillator
- WFF 0.00
- LPCN 67.24
About WFF WF Holding Limited Ordinary Shares
WF Holding Ltd is a manufacturer of FRP products based in Malaysia. It has been providing high-quality and durable FRP products to various industries, including, among others, chemical processing, water and wastewater treatment, and power generation. Its products range from tanks, pipes, ducts, gratings and other custom-made FRP products. The company uses advanced production technology and equipment and has obtained various certifications. Its manufacturing capabilities allow the company to design and fabricate products that meet the specific needs of its clients, ensuring high-quality and reliable performance.
About LPCN Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.